Literature DB >> 6090749

Establishment of lymphomatous cell lines from bone marrow samples from patients with Burkitt's lymphoma.

I Philip, T Philip, M Favrot, M Vuillaume, B Fontaniere, D Chamard, G M Lenoir.   

Abstract

A total of 233 bone marrow aspirates were obtained from 43 patients with Burkitt's lymphoma (BL). Lymphoma cells were absent and lymphoblastoid cell lines could not be established from 197 samples, which were characterized by limited initial cell proliferation and development of an adherent population, followed by cell death after 2-4 weeks. In 14 aspirates, after a similar pattern of growth, cell proliferation began again after about 6 weeks, with a rapid appearance and growth of cell clumps from the feeder layer--a type of growth typical of spontaneous lymphoblastoid cell lines. In 22 aspirates, growth of malignant cells was observed in culture and cytocentrifuged, stained smears, including marrow samples from 9 patients in whom the presence of BL cells had not been ascertained or even suspected by cytology. Karyotypic anomalies characteristic of BL were found in these cells: t(8;14) in the majority, two t(8;22), two t(2;8), and one t(2;8;9).

Entities:  

Mesh:

Year:  1984        PMID: 6090749

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

Authors:  S Torsteinsdottir; M G Masucci; B Ehlin-Henriksson; C Brautbar; H Ben Bassat; G Klein; E Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.

Authors:  René Winkler; Ann-Sophie Mägdefrau; Eva-Maria Piskor; Markus Kleemann; Mandy Beyer; Kevin Linke; Lisa Hansen; Anna-Maria Schaffer; Marina E Hoffmann; Simon Poepsel; Florian Heyd; Petra Beli; Tarik Möröy; Siavosh Mahboobi; Oliver H Krämer; Christian Kosan
Journal:  Oncogene       Date:  2022-09-06       Impact factor: 8.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.